prior authorization glp 1 Patients Face New Barriers for GLP-1 Drugs The ePA Process for GLP-1

In a study comparing tirzepatide and semaglutide, tirzepatide reduced HbA1c by 2.01% to 2.30%, depending on the dose, while semaglutide reduced it by 1.86% in 40 weeks 13

not all patients experience reflux symptoms on the medication

Optional Support Services For patients seeking additional guidance, we offer: Nutrition Counseling: Personalized meal planning with a registered dietitian

The same 5 mg vial reconstituted with 1 mL gives you 5 mg/mL

Zone-2 cardio and resistance training are particularly beneficial

In LEADER, the use of liraglutide was associated with a 0.4% HbA1c reduction compared with the placebo (Zinman et al., 2018)